APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumonia Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchPneumonia Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Pneumonia Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Pneumonia Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumonia Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumonia Vaccine market include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumonia Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumonia Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumonia Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumonia Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumonia Vaccine Segment by Company

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc.

Glaxosmithkline Plc.

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India Pvt. Ltd.

Sanofi Pasteur

Royal (Wuxi) Bio-Pharmaceutical

Emergent Biosolutions

CSL Limited

Astrazeneca Plc.

Astellas Pharma Inc.

Pneumonia Vaccine Segment by Type

Pneumococcal Conjugate Vaccine (PCV13)

Pneumococcal Polysaccharide Vaccine (PPSV23)

Other

Pneumonia Vaccine Segment by Application

Sepsis

Meningitis

Pneumonia

Pneumonia Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pneumonia Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumonia Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumonia Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumonia Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumonia Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumonia Vaccine industry.

Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumonia Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumonia Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumonia Vaccine Industry Trends Table 2. Pneumonia Vaccine Industry Drivers Table 3. Pneumonia Vaccine Industry Opportunities and Challenges Table 4. Pneumonia Vaccine Industry Restraints Table 5. Global Pneumonia Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumonia Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pneumonia Vaccine Sales Volume by Company (doses) & (2021-2026) Table 8. Global Pneumonia Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pneumonia Vaccine Average Price (US$/dose) of Company (2021-2026) Table 10. Global Pneumonia Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumonia Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pneumonia Vaccine Company, Product Type & Application Table 13. Global Pneumonia Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumonia Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pneumococcal Conjugate Vaccine (PCV13) Table 18. Significant Companies of Pneumococcal Polysaccharide Vaccine (PPSV23) Table 19. Significant Companies of Other Table 20. Global Pneumonia Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (doses) Table 21. Global Pneumonia Vaccine Sales Volume by Type (2021-2026) & (doses) Table 22. Global Pneumonia Vaccine Sales Volume by Type (2027-2032) & (doses) Table 23. Global Pneumonia Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Pneumonia Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Pneumonia Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pneumonia Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pneumonia Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pneumonia Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Pneumonia Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Sepsis Table 31. Significant Companies of Meningitis Table 32. Significant Companies of Pneumonia Table 33. Global Pneumonia Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (doses) Table 34. Global Pneumonia Vaccine Sales Volume by Application (2021-2026) & (doses) Table 35. Global Pneumonia Vaccine Sales Volume by Application (2027-2032) & (doses) Table 36. Global Pneumonia Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Pneumonia Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Pneumonia Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pneumonia Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pneumonia Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pneumonia Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Pneumonia Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Pneumonia Vaccine Sales by Region: 2021 VS 2025 VS 2032 (doses) Table 44. Global Pneumonia Vaccine Sales by Region (2021-2026) & (doses) Table 45. Global Pneumonia Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Pneumonia Vaccine Sales by Region (2027-2032) & (doses) Table 47. Global Pneumonia Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Pneumonia Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pneumonia Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pneumonia Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Pneumonia Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pneumonia Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Pneumonia Vaccine Market Average Price (US$/dose) by Region (2021-2026) Table 54. Global Pneumonia Vaccine Market Average Price (US$/dose) by Region (2027-2032) Table 55. Global Pneumonia Vaccine Sales by Country: 2021 VS 2025 VS 2032 (doses) Table 56. Global Pneumonia Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pneumonia Vaccine Sales by Country (2021-2026) & (doses) Table 58. Global Pneumonia Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Pneumonia Vaccine Sales by Country (2027-2032) & (doses) Table 60. Global Pneumonia Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Pneumonia Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pneumonia Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Pneumonia Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pneumonia Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Pneumonia Vaccine Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Merck & Co., Inc. Company Information Table 71. Merck & Co., Inc. Business Overview Table 72. Merck & Co., Inc. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 73. Merck & Co., Inc. Pneumonia Vaccine Product Portfolio Table 74. Merck & Co., Inc. Recent Development Table 75. Pfizer Inc. Company Information Table 76. Pfizer Inc. Business Overview Table 77. Pfizer Inc. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 78. Pfizer Inc. Pneumonia Vaccine Product Portfolio Table 79. Pfizer Inc. Recent Development Table 80. Glaxosmithkline Plc. Company Information Table 81. Glaxosmithkline Plc. Business Overview Table 82. Glaxosmithkline Plc. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 83. Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio Table 84. Glaxosmithkline Plc. Recent Development Table 85. Zhifei Biologic Company Information Table 86. Zhifei Biologic Business Overview Table 87. Zhifei Biologic Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 88. Zhifei Biologic Pneumonia Vaccine Product Portfolio Table 89. Zhifei Biologic Recent Development Table 90. Walvax Biotechnology Company Information Table 91. Walvax Biotechnology Business Overview Table 92. Walvax Biotechnology Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 93. Walvax Biotechnology Pneumonia Vaccine Product Portfolio Table 94. Walvax Biotechnology Recent Development Table 95. Serum Institute of India Pvt. Ltd. Company Information Table 96. Serum Institute of India Pvt. Ltd. Business Overview Table 97. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 98. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio Table 99. Serum Institute of India Pvt. Ltd. Recent Development Table 100. Sanofi Pasteur Company Information Table 101. Sanofi Pasteur Business Overview Table 102. Sanofi Pasteur Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 103. Sanofi Pasteur Pneumonia Vaccine Product Portfolio Table 104. Sanofi Pasteur Recent Development Table 105. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 106. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 107. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 108. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio Table 109. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 110. Emergent Biosolutions Company Information Table 111. Emergent Biosolutions Business Overview Table 112. Emergent Biosolutions Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 113. Emergent Biosolutions Pneumonia Vaccine Product Portfolio Table 114. Emergent Biosolutions Recent Development Table 115. CSL Limited Company Information Table 116. CSL Limited Business Overview Table 117. CSL Limited Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 118. CSL Limited Pneumonia Vaccine Product Portfolio Table 119. CSL Limited Recent Development Table 120. Astrazeneca Plc. Company Information Table 121. Astrazeneca Plc. Business Overview Table 122. Astrazeneca Plc. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 123. Astrazeneca Plc. Pneumonia Vaccine Product Portfolio Table 124. Astrazeneca Plc. Recent Development Table 125. Astellas Pharma Inc. Company Information Table 126. Astellas Pharma Inc. Business Overview Table 127. Astellas Pharma Inc. Pneumonia Vaccine Sales (doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 128. Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio Table 129. Astellas Pharma Inc. Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Pneumonia Vaccine Distributors List Table 133. Pneumonia Vaccine Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Pneumonia Vaccine Product Image Figure 2. Global Pneumonia Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumonia Vaccine Sales (2021-2032) & (doses) Figure 5. Global Pneumonia Vaccine Sales Average Price (US$/dose) & (2021-2032) Figure 6. Global Pneumonia Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pneumococcal Conjugate Vaccine (PCV13) Image Figure 10. Pneumococcal Polysaccharide Vaccine (PPSV23) Image Figure 11. Other Image Figure 12. Global Pneumonia Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (doses) Figure 13. Global Pneumonia Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pneumonia Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Pneumonia Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pneumonia Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pneumonia Vaccine Sales Value Share by Type (2021-2032) Figure 18. Sepsis Image Figure 19. Meningitis Image Figure 20. Pneumonia Image Figure 21. Global Pneumonia Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (doses) Figure 22. Global Pneumonia Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pneumonia Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Pneumonia Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pneumonia Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pneumonia Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Pneumonia Vaccine Sales by Region: 2021 VS 2025 VS 2032 (doses) Figure 28. Global Pneumonia Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pneumonia Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pneumonia Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pneumonia Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pneumonia Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pneumonia Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pneumonia Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pneumonia Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pneumonia Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pneumonia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pneumonia Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pneumonia Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Pneumococcal Conjugate Vaccine (PCV13)
  • Pneumococcal Polysaccharide Vaccine (PPSV23)
  • Other
Applications
  • Sepsis
  • Meningitis
  • Pneumonia
Companies covered
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Glaxosmithkline Plc.
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur
  • Royal (Wuxi) Bio-Pharmaceutical
  • Emergent Biosolutions
  • CSL Limited
  • Astrazeneca Plc.
  • Astellas Pharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumonia Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pneumonia Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumonia Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumonia Vaccine Market Dynamics
  1. 2.1 Pneumonia Vaccine Industry Trends
  2. 2.2 Pneumonia Vaccine Industry Drivers
  3. 2.3 Pneumonia Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumonia Vaccine Industry Restraints
3 Pneumonia Vaccine Market by Company
  1. 3.1 Global Pneumonia Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pneumonia Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pneumonia Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumonia Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pneumonia Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pneumonia Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumonia Vaccine Company Product Type and Application
  8. 3.8 Global Pneumonia Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumonia Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumonia Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumonia Vaccine Market by Type
  1. 4.1 Pneumonia Vaccine Type Introduction
  2. 4.1.1 Pneumococcal Conjugate Vaccine (PCV13)
  3. 4.1.2 Pneumococcal Polysaccharide Vaccine (PPSV23)
  4. 4.1.3 Other
  5. 4.2 Global Pneumonia Vaccine Sales Volume by Type
  6. 4.2.1 Global Pneumonia Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumonia Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pneumonia Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pneumonia Vaccine Sales Value by Type
  10. 4.3.1 Global Pneumonia Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumonia Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pneumonia Vaccine Sales Value Share by Type (2021-2032)
5 Pneumonia Vaccine Market by Application
  1. 5.1 Pneumonia Vaccine Application Introduction
  2. 5.1.1 Sepsis
  3. 5.1.2 Meningitis
  4. 5.1.3 Pneumonia
  5. 5.2 Global Pneumonia Vaccine Sales Volume by Application
  6. 5.2.1 Global Pneumonia Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumonia Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pneumonia Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pneumonia Vaccine Sales Value by Application
  10. 5.3.1 Global Pneumonia Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumonia Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pneumonia Vaccine Sales Value Share by Application (2021-2032)
6 Pneumonia Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pneumonia Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumonia Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumonia Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumonia Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pneumonia Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumonia Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumonia Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumonia Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumonia Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumonia Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pneumonia Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumonia Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumonia Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumonia Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumonia Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumonia Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pneumonia Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumonia Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumonia Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pneumonia Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pneumonia Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumonia Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumonia Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumonia Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumonia Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pneumonia Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumonia Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumonia Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumonia Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumonia Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumonia Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Glaxosmithkline Plc.
  20. 8.4.1 Glaxosmithkline Plc. Company Information
  21. 8.4.2 Glaxosmithkline Plc. Business Overview
  22. 8.4.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
  24. 8.4.5 Glaxosmithkline Plc. Recent Developments
  25. 8.5 Zhifei Biologic
  26. 8.5.1 Zhifei Biologic Company Information
  27. 8.5.2 Zhifei Biologic Business Overview
  28. 8.5.3 Zhifei Biologic Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
  30. 8.5.5 Zhifei Biologic Recent Developments
  31. 8.6 Walvax Biotechnology
  32. 8.6.1 Walvax Biotechnology Company Information
  33. 8.6.2 Walvax Biotechnology Business Overview
  34. 8.6.3 Walvax Biotechnology Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
  36. 8.6.5 Walvax Biotechnology Recent Developments
  37. 8.7 Serum Institute of India Pvt. Ltd.
  38. 8.7.1 Serum Institute of India Pvt. Ltd. Company Information
  39. 8.7.2 Serum Institute of India Pvt. Ltd. Business Overview
  40. 8.7.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Pvt. Ltd. Recent Developments
  43. 8.8 Sanofi Pasteur
  44. 8.8.1 Sanofi Pasteur Company Information
  45. 8.8.2 Sanofi Pasteur Business Overview
  46. 8.8.3 Sanofi Pasteur Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
  48. 8.8.5 Sanofi Pasteur Recent Developments
  49. 8.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 8.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 8.9.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
  54. 8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 8.10 Emergent Biosolutions
  56. 8.10.1 Emergent Biosolutions Company Information
  57. 8.10.2 Emergent Biosolutions Business Overview
  58. 8.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
  60. 8.10.5 Emergent Biosolutions Recent Developments
  61. 8.11 CSL Limited
  62. 8.11.1 CSL Limited Company Information
  63. 8.11.2 CSL Limited Business Overview
  64. 8.11.3 CSL Limited Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 CSL Limited Pneumonia Vaccine Product Portfolio
  66. 8.11.5 CSL Limited Recent Developments
  67. 8.12 Astrazeneca Plc.
  68. 8.12.1 Astrazeneca Plc. Company Information
  69. 8.12.2 Astrazeneca Plc. Business Overview
  70. 8.12.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
  72. 8.12.5 Astrazeneca Plc. Recent Developments
  73. 8.13 Astellas Pharma Inc.
  74. 8.13.1 Astellas Pharma Inc. Company Information
  75. 8.13.2 Astellas Pharma Inc. Business Overview
  76. 8.13.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
  78. 8.13.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumonia Vaccine Value Chain Analysis
  2. 9.1.1 Pneumonia Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumonia Vaccine Sales Mode & Process
  6. 9.2 Pneumonia Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumonia Vaccine Distributors
  9. 9.2.3 Pneumonia Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst